Phase 4
N=315
Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
Hypertension · Left Ventricular Hypertrophy
Bottom Line
View on ClinicalTrials.gov: NCT00348686 ↗Enrolled (actual)
315
Serious AEs
—
Results posted
Apr 2012
Primary outcome: Primary: Percent Change of B Type Natriuretic Peptides (BNP) Level — -29.2 Percent Change
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Candesartan (Drug); Felodipine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- AstraZeneca
- Primary completion
- Jun 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change of B Type Natriuretic Peptides (BNP) Level |
-29.2 | — |
| SECONDARY LVH(Left Ventricular Hypertrophy) Regression by Echocardiac Parameter, Left Ventricular Mass Index |
-10.90 | — |
| SECONDARY Change of Systolic Blood Pressure (SBP) |
-32.0 | — |
| SECONDARY Change of Diastolic Blood Pressure (DBP) |
-20.0 | — |
| SECONDARY Percent Change of proBNP(B Type Natriuretic Peptides) in Patients Treated With Candesartan Only |
-18.9 | — |
| SECONDARY Percent Change of proBNP(B Type Natriuretic Peptides) in Patients With Candesartan Plus Felodipine |
-36.1 | — |
Summary
The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.
Eligibility Criteria
Inclusion Criteria
- Hypertension with diastolic blood pressure within 95-115 mm/Hg or/and systolic blood pressure within 160-200 mm/Hg
- Patients diagnosed as left ventricular hypertrophy by electrocardiogram
Exclusion Criteria
- Secondary hypertension
- History of myocardial infarction
- Stroke within the previous 6 months
Data sourced from ClinicalTrials.gov (NCT00348686). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.